The global drug market for non-small lung cancer is forecasted to grow as treatments grow adverse and variedPress release September 17, 2014 Non small cell lung cancer treatment, non small cell lung cancer therapy
The report focuses on the increasing differentiation between the three main NSCLC subtypes: squamous cell, adenocarcinoma, and large cell carcinoma.
The global drug market for non-small cell lung cancer is estimated to increase from USD 4.3 billion in 2009 to USD 6.9 billion in 2019. The market is expected to grow at a CAGR of 4.84%. The key regions for growth for the non-small cell lung cancer treatment are France, United States, Germany, Italy, United Kingdom, Japan and Germany. The global top five brands developing drugs or conducting clinical trials are Tarceva, Alimta, Avastin, Taxotere, and Gemzar.
This report, Non-Small Cell Lung Cancer Market to 2020 - New Therapies to Enhance Treatment Segmentation and Drive Growth in an Increasingly Competitive Market focuses on the increasing differentiation between the three main NSCLC subtypes: squamous cell, adenocarcinoma, and large cell carcinoma.
The overall value of the market is expected to increase and the growth of the sector can be accredited to the various novel therapies, especially for squamous cell carcinoma that currently lacks any effective treatment method. Other prospects of the treatment including common genetic and molecular aberrations within these histologies, are being extensively researched. According to market experts, patients with squamos cell carcinoma are set to benefit from the crucial clinical treatments and second line therapies.
On the other hand, the non-squamous patients already have several histology specific therapies and mutation specific therapies that are already dominating the market. Improved second line treatment methods will create a competitive environment for those that exist. Alimta and Tarceva are however, expected to fight for their dominance and create competition for the new entrants who have currently shown only minor improvements in safety and efficiency of their treatments.
Despite such growth opportunities and identification of several molecular targets, most products still remain in the early stage of development. The market will however, continue to grow towards personalized medicine through 2019, which would give birth to a fragmented market. Of the two players, Alimta and Tarceva even Avastin will also maintain a steady uptake.
The new emerging markets of non-small lung cancer treatment have increased the penetration of the available drug treatments and some of the big players of the market are AstraZeneca’s Roche’s and Merck’s KGaA’s are the main driving force of the market.
For further insights,
About Research on Global Markets
Research on Global Markets is a leading source for market research on various sectors globally, offering premium research content from worldwide publishers of market research reports. Our database hosts premium market research content developed by global publishers. It offers premium industry research reports, company profiles and country briefs. We have a dedicated team of research professionals who can facilitate, in an unbiased manner, the process of identifying appropriate market research reports that are targeted to fulfill all your information-related requirements.
For more details on the content of each report and ordering information please contact:
Email: custome[email protected]
US: +1 800 986 6819
UK: +44 203 514 2363
India: +91 22 4098 7600
Non small cell lung cancer treatment, non small cell lung cancer therapy